CYP2B6 genetic polymorphisms influence chronic obstructive pulmonary disease susceptibility in the Hainan population

References

• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: The GOLD science committee report 2019. Eur Respir J. 2019;53:1900164. doi:10.1183/13993003.00164-201930846476
   PubMed Web of Science ®Google Scholar
• Ding Y, Niu H, Yang H, et al. EGLN2 and RNF150 genetic variants are associated with chronic obstructive pulmonary disease risk in the Chinese population. Int J Chron Obstruct Pulmon Dis. 2015;10:145–151. doi:10.2147/COPD.S7303125609945
   PubMed Web of Science ®Google Scholar
• Monick MM, Beach SR, Plume J, et al. Coordinated changes in AHRR methylation in lymphoblasts and pulmonary macrophages from smokers. Am J Med Genet B Neuropsychiatr Genet. 2012;159b(2):141–151. doi:10.1002/ajmg.b.3202122232023
   PubMed Web of Science ®Google Scholar
• Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523–532. doi:10.1183/09031936.06.0012460516611654
   PubMed Web of Science ®Google Scholar
• Wang X, Li L, Xiao J, et al. Association of ADAM33 gene polymorphisms with COPD in a northeastern Chinese population. BMC Med Genet. 2009;10:132. doi:10.1186/1471-2350-10-13220003279
   PubMed Web of Science ®Google Scholar
• Xiong M, Wang J, Guo M, Zhou Q, Lu W. TRPM8 genetic variations associated with COPD risk in the Chinese Han population. Int J Chron Obstruct Pulmon Dis. 2016;11:2563–2571. doi:10.2147/COPD.S10902627789940
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.003044217132052
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256–1276. doi:10.1164/ajrccm.163.5.210103911316667
   PubMedGoogle Scholar
• Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009;5(3):e1000421. doi:10.1371/journal.pgen.100042119300482
   PubMed Web of Science ®Google Scholar
• Bengt ZL, Xinjun L, Jan S, Kristina S. Familial transmission of chronic obstructive pulmonary disease in adoptees: a Swedish nationwide family study. BMJ Open. 2015;5(4):e007310. doi:10.1136/bmjopen-2014-007310
   Web of Science ®Google Scholar
• Silverman EK, Vestbo J, Agusti A, et al. Opportunities and challenges in the genetics of COPD 2010: an International COPD genetics conference report. Copd. 2011;8(2):121–135. doi:10.3109/15412555.2011.55886421495840
   PubMedGoogle Scholar
• Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996;6(1):1–42.8845856
   PubMedGoogle Scholar
• Lamba V, Lamba J, Yasuda K, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307(3):906–922. doi:10.1124/jpet.103.05486614551287
   PubMed Web of Science ®Google Scholar
• Court MH, Duan SX, Hesse LM, Venkatakrishnan K, Greenblatt DJ. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001;94(1):110–119. doi:10.1097/00000542-200101000-0002111135730
   PubMed Web of Science ®Google Scholar
• Hodgson E, Rose RL. The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals. Pharmacol Ther. 2007;113(2):420–428. doi:10.1016/j.pharmthera.2006.10.00217157385
   PubMed Web of Science ®Google Scholar
• Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos. 1997;25(8):985–993.9280407
   PubMed Web of Science ®Google Scholar
• Thum T, Borlak J. Gene expression in distinct regions of the heart. Lancet. 2000;355(9208):979–983. doi:10.1016/S0140-6736(00)99016-010768437
   PubMed Web of Science ®Google Scholar
• Gervot L, Rochat B, Gautier JC, et al. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics. 1999;9(3):295–306.10471061
   PubMedGoogle Scholar
• Demura SA, Kogan EA, Goryachkina VL. [Chronic diseases, precancer, and cancer of the lung, which are associated with pathology of the club cells of respiratory and terminal bronchioles]. Arkh Patol. 2018;80(5):63–68. doi:10.17116/patol20188005163
   Google Scholar
• Mace K, Bowman ED, Vautravers P, Shields PG, Harris CC, Pfeifer AM. Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur J Cancer. 1998;34(6):914–920. doi:10.1016/s0959-8049(98)00034-39797707
   PubMed Web of Science ®Google Scholar
• Hukkanen J, Pelkonen O, Hakkola J, Raunio H. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol. 2002;32(5):391–411. doi:10.1080/2002409106427312389869
   PubMed Web of Science ®Google Scholar
• Ding Y, Yang D, Xun X, et al. Association of genetic polymorphisms with chronic obstructive pulmonary disease in the Hainan population: a case-control study. Int J Chron Obstruct Pulmon Dis. 2015;10:7–13. doi:10.2147/COPD.S7304225565795
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP28128970
   PubMed Web of Science ®Google Scholar
• Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. 2009; 60: 2.12.1–2.12.18. doi: 10.1002/0471142905.hg0212s60
   PubMedGoogle Scholar
• Ding Y, Yang D, Zhou L, et al. Variants in multiple genes polymorphism association analysis of COPD in the Chinese Li population. Int J Chron Obstruct Pulmon Dis. 2015;10:1455–1463. doi:10.2147/COPD.S8672126251585
   PubMed Web of Science ®Google Scholar
• Clarke GM, Anderson CA, Pettersson FH, Cardon LR, Morris AP, Zondervan KT. Basic statistical analysis in genetic case-control studies. Nat Protoc. 2011;6(2):121–133. doi:10.1038/nprot.2010.18221293453
   PubMed Web of Science ®Google Scholar
• Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007;8(7):743–759. doi:10.2217/14622416.8.7.74317638512
   PubMed Web of Science ®Google Scholar
• Berkoz M, Yalin S. Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility. Leuk Res. 2009;33(7):919–923. doi:10.1016/j.leukres.2008.11.01419144407
   PubMed Web of Science ®Google Scholar
• Hoffman SM, Nelson DR, Keeney DS. Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics. 2001;11(8):687–698.11692077
   PubMedGoogle Scholar
• Hofmann MH, Blievernicht JK, Klein K, et al. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther. 2008;325(1):284–292. doi:10.1124/jpet.107.13330618171905
   PubMed Web of Science ®Google Scholar
• Tong K, He ML, Lin CK, et al. The implications of a high allelic frequency of CYP2B6 G516T in ethnic Chinese persons. Clin Infect Dis. 2006; 43(4):541–542; author reply 542–544. doi:10.1086/505984
   Web of Science ®Google Scholar